Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.
Claudia A M StegeKazem NasserinejadEllen van der SpekYavuz M BilginAlain KentosMaaike SohneRoel J W van KampenInge LudwigNoortje ThielenNazik Durdu-RaymanNicole C H P de GraauwNiels W C J van de DonkEsther G M de WaalMarie-Christiane VekemansGert Jan TimmersMarjolein van der KliftSavita SoechitPaulus A F GeertsMatthijs H SilbermannMargriet OosterveldInger S NijhofPieter SonneveldSaskia K KleinMark-David LevinSonja ZweegmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Ixa-Dara-dex lead to a high response rate and improved quality of life. However, treatment discontinuation because of toxicity and early mortality, negatively influencing PFS and OS, remains a concern in frail patients. The outcome was heterogeneous across frail subpopulations. This should be taken into account in the design and interpretation of future studies in frail patients, to pave the way for more precise treatment guidance.